ESMO2016 Eye on ESMO: Day 2 - gamechangers take centre stage Novartis’ phase 3 advanced breast cancer therapy ribociclib shows promise
ESMO2016 Eye on ESMO: Day 1 - Access in spotlight before data deluge Europe's biggest cancer conference ESMO is underway
Partner Content Partner Content On Demand: The Top 5 Challenges in Immuno-Oncology Trials In the battle against cancer, immunotherapy is proving to be one of the most promising avenues of research.
Articles A breakthrough in lung cancer - the biggest prize in immunot... AstraZeneca/MedImmune hopes its immunotherapy combinations will help it catch up with leaders.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
